Replies to post #22663 on RespireRx Pharmaceuticals Inc (fka RSPI)

[neuroinv]

There are different levels of 'insiders.' Benedik, as a BOD member, is most likely not being updated about the day to day status of discussions/negotiations. The BOD would be asked to approve a finalized deal, so his purchase on 1/13/09 simply means that as of that time, no deal had been finalized and presented to the BOD. If one had, it would have been publicly disclosed by now. So it doesnt mean anything definitively good or bad. If one wants to presume some inference of how he is reading whatever indications are available to him, it's not a negative.

NeuroInvestment

[atheroprevent]

Also Rusbrn, as RBlatch has noted on previous occasions, no one is leaving Cor.

OT, of interest buyout whispers about CVTX, up 15% today on large volume. I don't know if it is real or who the suiter(s) might be. A new class antianginal with favorable metabolic profile might fill the bill for BP (near term profitability with Ranexa and large growth potential for BP with good CV/Metabolic sales force).

Jerry, CVTX reminds me of AMLN, not just because they have similar 11 dollar SP, but because of their potential turn to profitability + double in 2009 and/or buyout.

CVTX and AMLN have fought the same FDA delaying headwinds as COR. It is a universal condition in biotechland.

It is probably worth a repeat mention that AMLN story includes a period when company pulled itself up from a 27 cent SP valuation in Oct 1998.